Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 29Neoplasms 10Brain Neoplasms 6Neoplasm Metastasis 3Thyroid Neoplasms 2Thyroid Cancer, Papillary 2Skin Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Thyroid Carcinoma, Anaplastic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Lymphoma 1Leukemia, Hairy Cell 1Histiocytosis, Langerhans-Cell 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Ganglioneuroma 1Ganglioglioma 1Fever 1Differentiated Thyroid Cancer (DTC) 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 14Bevacizumab 11Erlotinib Hydrochloride 5Radiotherapy 4Carboplatin 4Magnetic Resonance Spectroscopy 3Irinotecan 3Immunoglobulin G 3Disulfides 3temsirolimus 2poly ICLC 2palbociclib 2etoposide phosphate 2antineoplaston AS 2-1 2antineoplaston A10 2Vincristine 2Sunitinib 2Sirolimus 2Everolimus 2Dasatinib 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2veliparib 1varlilumab 1vandetanib 1trebananib 1trametinib 1terameprocol 1tandutinib 1selinexor 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Oligodendroglioma × dabrafenib × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡